Adalimumab Therapy Effective In AS, RA And PsA Patients Refractory To Other Anti-TNF Therapies

Adalimumab therapy is effective and well-tolerated in ankylosing spondylitis, rheumatoid arthritis and psoriatic arthritis patients with a previously inadequate response to anti-tumour necrosis factor therapies etanercept and infliximab, according to new research.

Read the whole article on Science Daily

More from Science Daily